logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5127.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5127.produseast1
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus | Conference Material / Video | MSF Science Portal
Conference Material
|Video

Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus

Yatskevich N
Similar Content
Slide Presentation
|Slide Presentation
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Abstract
|Abstract
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Loading...

Countries

Belarus

Subject Area

antibiotic resistancetuberculosisantimicrobial resistance

Languages

English
DOI
10.57740/7dx0-kq64
Published Date
07 Jun 2023
Conference
MSF Scientific Day International 2023
Linked Content
Conference Material
|Slide Presentation
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023
Conference Material
|Abstract
Preliminary data on safety and effectiveness of six-month all-oral regimens in patients with rifampicin-resistant tuberculosis in Belarus
2023 June 07 • MSF Scientific Day International 2023